Post-marketing observational program of the effectiveness of fluvoxamine for the treatment of depression in patients with neurological disorders: the FRIENDS study

In a prospective, non-blinded, uncontrolled, multicenter, post-marketing, observational study (FRIENDS; NCT02043197), fluvoxamine (50–300 mg/day for 90 days) was effective for the treatment of depression in 299 adult patients (age ≥18 years) with neurological disorders at baseline. The therapeutic e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahno, Nikolay N, Fedotova, Anastasia V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679672/
https://www.ncbi.nlm.nih.gov/pubmed/29138569
http://dx.doi.org/10.2147/NDT.S145614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679672/
https://www.ncbi.nlm.nih.gov/pubmed/29138569
http://dx.doi.org/10.2147/NDT.S145614

Ejemplares similares